Library Subscription: Guest
Journal of Environmental Pathology, Toxicology and Oncology

Published 4 issues per year

ISSN Print: 0731-8898

ISSN Online: 2162-6537

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.4 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.8 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.5 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00049 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.59 SJR: 0.429 SNIP: 0.507 CiteScore™:: 3.9 H-Index: 49

Indexed in

Novel Approaches for Colon Cancer Prevention by Cyclooxygenase-2 Inhibitors

Volume 21, Issue 2, 2002, 10 pages
DOI: 10.1615/JEnvironPatholToxicolOncol.v21.i2.90
Get accessGet access

ABSTRACT

During recent years, multidisciplinary studies in epidemiology and molecular biology, as well as preclinical studies, have contributed much to our understanding of the etiology of colorectal cancer; more importantly they have enabled us to approach its prevention. An impressive body of epidemiological data suggests an inverse relationship between colorectal cancer risk and regular use of nonsteroidal antiinflammatory drugs (NSAIDs), including aspirin. Clinical trials with NSAIDs have demonstrated that NSAID treatment caused regression of preexisting colon adenomas in patients with familial adenomatous polyposis. Preclinical efficacy studies have provided compelling evidence that several phytochemicals with antiinflammatory properties and NSAIDs act to retard, block, or reverse colon carcinogenesis. Equally exciting are opportunities for effective chemoprevention with selective cyclooxygenase-2 (COX-2) inhibitors including celecoxib and rofecoxib in a variety of preclinical models of colon cancer. Naturally occurring COX-2 inhibitors such as curcumin and certain phytosterols have been proven to be effective as chemopreventive agents against colon carcinogenesis with minimal gastrointestinal toxicity. Multistep process of carcinogenesis has provided substantial insights into the mechanisms by which naturally occurring and synthetic antiinflammatory agents modulate these events leading to suppression of tumorigenesis. Growing knowledge in this area has brought about innovative approaches using a combination of agents with different modes of action as a means of increasing efficacy and minimizing toxicity. The natural history of colorectal cancer, from dysplastic aberrant crypts to adenomas and adenocarcinomas, offers multiple opportunities for assessment and intervention. Of further importance would be to identify molecular targets that are critical in the growth and survival of the malignant colorectal cell and are modulated by NSAIDs and COX-2 inhibitors.

CITED BY
  1. Sales Gloria Sabater, Tobella Juan Sabater, Nutrigenética y nutrigenómica, in Medicina Personalizada Posgenómica. Conceptos Prácticos Para Clínicos, 2010. Crossref

  2. Ding Haiming, Han Chunhua, Zhu Jiuxiang, Chen Ching-Shih, D'Ambrosio Steven M., Celecoxib derivatives induce apoptosisvia the disruption of mitochondrial membrane potential and activation of caspase 9, International Journal of Cancer, 113, 5, 2005. Crossref

  3. Tudek Barbara, Speina Elżbieta, Oxidatively damaged DNA and its repair in colon carcinogenesis, Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 736, 1-2, 2012. Crossref

  4. Nasir Aejaz, Kaiser Hans E., Boulware David, Hakam Ardeshir, Zhao Helena, Yeatman Timothy, Barthel James, Coppola Domenico, Cyclooxygenase-2 Expression in Right- and Left-Sided Colon Cancer: A Rationale For Optimization of Cyclooxygenase-2 Inhibitor Therapy, Clinical Colorectal Cancer, 3, 4, 2004. Crossref

  5. Misra Suniti, Ghatak Shibnath, Patil Neha, Dandawate Prasad, Ambike Vinita, Adsule Shreelekha, Unni Deepak, Venkateswara Swamy K., Padhye Subhash, Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan–CD44v6 pathway and inducing cytotoxicity in colon cancer cells, Bioorganic & Medicinal Chemistry, 21, 9, 2013. Crossref

  6. Rao Chinthalapally V., Patlolla Jagan M.R., Cooma Indrani, Kawamori Toshihiko, Steele Vernon E., Prevention of Familial Adenomatous Polyp Development inAPCminMice and Azoxymethane-Induced Colon Carcinogenesis in F344 Rats by ω-3 Fatty Acid Rich Perilla Oil, Nutrition and Cancer, 65, sup1, 2013. Crossref

  7. Hayashi Shigeo, Ueno Naomi, Murase Akio, Takada Junji, Design, synthesis and structure–activity relationship studies of novel and diverse cyclooxygenase-2 inhibitors as anti-inflammatory drugs, Journal of Enzyme Inhibition and Medicinal Chemistry, 29, 6, 2014. Crossref

  8. Cottam Howard B., Antiaging Agents, in Kirk-Othmer Encyclopedia of Chemical Technology, 2003. Crossref

  9. Kim Sylvia Jeewon, Hellerstein Marc K., Pharmacological doses of dietary curcumin increase colon epithelial cell proliferationin vivo in rats, Phytotherapy Research, 21, 10, 2007. Crossref

  10. Yamada Hiroshi Y., Yao Yixin, Wang Xiaoxing, Zhang Yuting, Huang Ying, Dai Wei, Rao Chinthalapally V., Haploinsufficiency ofSGO1results in deregulated centrosome dynamics, enhanced chromosomal instability and colon tumorigenesis, Cell Cycle, 11, 3, 2012. Crossref

  11. Rathore Ankita, Rahman Mujeeb Ur, Siddiqui Anees Ahamad, Ali Abuzer, Shaharyar Mohammad, Design and Synthesis of Benzimidazole Analogs Endowed with Oxadiazole as Selective COX-2 Inhibitor, Archiv der Pharmazie, 347, 12, 2014. Crossref

  12. Misra Suniti, Ghatak Shibnath, Vyas Alok, O’Brien Paul, Markwald Roger R., Khetmalas Madhukar, Hascall Vincent C., McCarthy James B., Karamanos Nikos K., Tammi Markku I., Tammi Raija H., Prestwitch Glenn D., Padhye Subhash, Isothiocyanate analogs targeting CD44 receptor as an effective strategy against colon cancer, Medicinal Chemistry Research, 23, 8, 2014. Crossref

  13. Rao Chinthalapally V., Janakiram Naveena B., Mohammed Altaf, Lipoxygenase and Cyclooxygenase Pathways and Colorectal Cancer Prevention, Current Colorectal Cancer Reports, 8, 4, 2012. Crossref

  14. Surh Young-Joon, Na Hye-Kyung, Joo Lee Hyong, Chemopreventive Effects of Selected Spice Ingredients, in Phytopharmaceuticals in Cancer Chemoprevention, 20041296, 2004. Crossref

  15. Bocca Claudia, Bozzo Francesca, Ievolella Monica, Miglietta Antonella, A novel nitro-oxy substituted analogue of rofecoxib reduces human colon cancer cell growth, Molecular and Cellular Biochemistry, 361, 1-2, 2012. Crossref

  16. Ahuja Naveen, Singh Amarjit, Singh Bhupinder, Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects, Journal of Pharmacy and Pharmacology, 55, 7, 2010. Crossref

  17. Rosenkranz Herbert, Thampatty Bhavani, Applications of Substructure-Based SAR in Toxicology, in Predictive Toxicology, 2005. Crossref

  18. Mohammed Altaf, Janakiram Naveena B, Brewer Misty, Vedala Krishna, Steele Vernon E, Rao Chinthalapally V, Multitargeted Low-Dose GLAD Combination Chemoprevention: A Novel and Promising Approach to Combat Colon Carcinogenesis, Neoplasia, 15, 5, 2013. Crossref

  19. Schiffmann Susanne, Maier Thorsten Jürgen, Wobst Ivonne, Janssen Astrid, Corban-Wilhelm Heike, Angioni Carlo, Geisslinger Gerd, Grösch Sabine, The anti-proliferative potency of celecoxib is not a class effect of coxibs, Biochemical Pharmacology, 76, 2, 2008. Crossref

  20. Lynch Henry T, Tinley Susan T, Shaw Trudy G, Lynch Jane F, Howe James R, Attard Thomas M, Challenging colonic polyposis pedigrees: differential diagnosis, surveillance, and management concerns, Cancer Genetics and Cytogenetics, 148, 2, 2004. Crossref

  21. Hayashi Shigeo, Sumi Yoko, Ueno Naomi, Murase Akio, Takada Junji, Discovery of a novel COX-2 inhibitor as an orally potent anti-pyretic and anti-inflammatory drug: Design, synthesis, and structure–activity relationship, Biochemical Pharmacology, 82, 7, 2011. Crossref

  22. Rüegg Curzio, Zaric Jelena, Stupp Roger, Non steroidal anti‐inflammatory drugs and COX‐2 inhibitors as anti‐cancer therapeutics: hypes, hopes and reality, Annals of Medicine, 35, 7, 2003. Crossref

  23. Narayanan Narayanan, Narayanan Bhagavathi, Reddy Bandaru, Omega-3 Polyunsaturated Fatty Acid Against Colon Cancer, in Unraveling Lipid Metabolism With Microarrays, 2004. Crossref

  24. Cen Hui, Induction of HSF1 expression is associated with sporadic colorectal cancer, World Journal of Gastroenterology, 10, 21, 2004. Crossref

  25. Wu Ai-Wen, Role of COX-2 in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients’ prognosis, World Journal of Gastroenterology, 9, 9, 2003. Crossref

  26. Niranjana Sri Sundaramoorthy, Thiagarajan Raman, Manikandan Ramar, Arumugam Munuswamy, Curcumin-Based Food Supplements: Challenges and Future Prospects, in Nonvitamin and Nonmineral Nutritional Supplements, 2019. Crossref

  27. Ding Haiming, Han Chunhua, Gibson-D?Ambrosio Ruth, Steele Vernon E., D?Ambrosio Steven M., Piroxicam selectively inhibits the growth of premalignant and malignant human oral cell lines by limiting their progression through the S phase and reducing the levels of cyclins and AP-1, International Journal of Cancer, 107, 5, 2003. Crossref

  28. Suwa Yusuke, Watanabe Jun, Ota Mitsuyoshi, Suzuki Shinsuke, Suwa Hirokazu, Watanabe Kazuteru, Saito Shuji, Nagamine Koutaro, Momiyama Masashi, Ishibe Atsushi, Saigusa Yusuke, Yamanaka Takeharu, Endo Itaru, Randomized phase II trial of the prophylactic use of celecoxib for the prevention of oxaliplatin-related peripheral vascular pain in Capeox (YCOG1205), Cancer Chemotherapy and Pharmacology, 83, 3, 2019. Crossref

  29. Mohammed Altaf, Yarla Nagendra Sastry, Madka Venkateshwar, Rao Chinthalapally V., Clinically Relevant Anti-Inflammatory Agents for Chemoprevention of Colorectal Cancer: New Perspectives, International Journal of Molecular Sciences, 19, 8, 2018. Crossref

  30. Grab Leslie T, Kearns Mary W, Morris Andrew J, Daniel Larry W, Differential role for phospholipase D1 and phospholipase D2 in 12-O-tetradecanoyl-13-phorbol acetate-stimulated MAPK activation, Cox-2 and IL-8 expression, Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 1636, 1, 2004. Crossref

  31. Brabletz T., In Vivo Functions of Catenins, in Cell Adhesion, 165, 2004. Crossref

  32. Aggarwal Bharat B., Sundaram Chitra, Malani Nikita, Ichikawa Haruyo, CURCUMIN: THE INDIAN SOLID GOLD, in The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease, 595, 2007. Crossref

  33. Feng Yi, Neale Jason R., Doll Mark A., Hein David W., Chemoprevention of Arylamine-Induced Colorectal Aberrant Crypts, Experimental Biology and Medicine, 233, 1, 2008. Crossref

  34. Viviano Katrina R., Pharmacotherapeutics of Cancer, in Pharmacotherapeutics for Veterinary Dispensing, 2019. Crossref

  35. Lof Marie, Olivo-Marston Susan, Hilakivi-Clarke Leena, n-6 Polyunsaturated Fatty Acids and Cancer, in Bioactive Compounds and Cancer, 2010. Crossref

  36. Lynch Henry, Shaw Trudy, Lynch Jane, Roy Hemant, Nonsteroidal Anti-Inflammatory Drugs (NSAID) and Colorectal Cancer, in Phytopharmaceuticals in Cancer Chemoprevention, 20041296, 2004. Crossref

  37. El-Hady Shaymaa M., AbouGhaly Mohamed H.H., El-Ashmoony Manal M., Helmy Hebatullah S., El-Gazayerly Omaima N., Colon targeting of celecoxib nanomixed micelles using pulsatile drug delivery systems for the prevention of inflammatory bowel disease, International Journal of Pharmaceutics, 576, 2020. Crossref

  38. Surh Young-Joon, Chemopreventive Phenolic Compounds in Common Spices, in Carcinogenic and Anticarcinogenic Food Components, 20054980, 2005. Crossref

  39. Janakiram Naveena B., Rao Chinthalapally V., The Role of Inflammation in Colon Cancer, in Inflammation and Cancer, 816, 2014. Crossref

  40. Anant Shrikant, Sureban Sripathi M., Cyclooxygenase-2 Gene Expression, in Apoptosis, Cell Signaling, and Human Diseases, 2007. Crossref

  41. Miyamoto Shingo, Suzuki Rikako, Yasui Yumiko, Kohno Hiroyuki, Sugie Shigeyuki, Murakami Akira, Ohigashi Hajime, Tanaka Takuji, Lack of Enhancing Effect of Lauric Acid on the Development of Aberrant Crypt Foci in Male ICR Mice Treated with Azoxymethane and Dextran Sodium Sulfate, Journal of Toxicologic Pathology, 20, 2, 2007. Crossref

  42. Lau Clara Bik-San, Yue Grace Gar-Lee, Adjuvant Value of Turmeric Extract (Containing Curcumin) in Colorectal Cancer Management, in Natural Products for Cancer Chemoprevention, 2020. Crossref

  43. Mohammed Altaf, Janakiram Naveena B., Li Qian, Choi Chang-In, Zhang Yuting, Steele Vernon E., Rao Chinthalapally V., Chemoprevention of Colon and Small Intestinal Tumorigenesis in APCMin/+ Mice by Licofelone, a Novel Dual 5-LOX/COX Inhibitor: Potential Implications for Human Colon Cancer Prevention, Cancer Prevention Research, 4, 12, 2011. Crossref

  44. Reddy Bandaru S., Wang Chung Xiou, Kong Ah-Ng, Khor Tin Oo, Zheng Xi, Steele Vernon E., Kopelovich Levy, Rao Chinthalapally V., Prevention of Azoxymethane-Induced Colon Cancer by Combination of Low Doses of Atorvastatin, Aspirin, and Celecoxib in F 344 Rats, Cancer Research, 66, 8, 2006. Crossref

  45. Weisberg S, Leibel R, Tortoriello D V, Proteasome inhibitors, including curcumin, improve pancreatic β-cell function and insulin sensitivity in diabetic mice, Nutrition & Diabetes, 6, 4, 2016. Crossref

  46. Griesser Markus, Pistis Valentina, Suzuki Takashi, Tejera Noemi, Pratt Derek A., Schneider Claus, Autoxidative and Cyclooxygenase-2 Catalyzed Transformation of the Dietary Chemopreventive Agent Curcumin, Journal of Biological Chemistry, 286, 2, 2011. Crossref

  47. Swamy Malisetty V., Cooma Indranie, Patlolla Jagan M.R., Simi Barbara, Reddy Bandaru S., Rao Chinthalapally V., Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: Novel strategies for colon cancer prevention and treatment, Molecular Cancer Therapeutics, 3, 2, 2004. Crossref

  48. Suh Nanjoo, Reddy Bandaru S., DeCastro Andrew, Paul Shiby, Lee Hong Jin, Smolarek Amanda K., So Jae Young, Simi Barbara, Wang Chung Xiou, Janakiram Naveena B., Steele Vernon, Rao Chinthalapally V., Combination of Atorvastatin with Sulindac or Naproxen Profoundly Inhibits Colonic Adenocarcinomas by Suppressing the p65/β-Catenin/Cyclin D1 Signaling Pathway in Rats, Cancer Prevention Research, 4, 11, 2011. Crossref

  49. Suh Nanjoo, Paul Shiby, Hao Xingpei, Simi Barbara, Xiao Hang, Rimando Agnes M., Reddy Bandaru S., Pterostilbene, an Active Constituent of Blueberries, Suppresses Aberrant Crypt Foci Formation in the Azoxymethane-Induced Colon Carcinogenesis Model in Rats, Clinical Cancer Research, 13, 1, 2007. Crossref

  50. Reddy Bandaru S., Patlolla Jagan M., Simi Barbara, Wang S.H., Rao Chinthalapally V., Prevention of Colon Cancer by Low Doses of Celecoxib, a Cyclooxygenase Inhibitor, Administered in Diet Rich in ω-3 Polyunsaturated Fatty Acids, Cancer Research, 65, 17, 2005. Crossref

  51. Rao Chinthalapally V., Steele Vernon E., Swamy Malisetty V., Patlolla Jagan M.R., Guruswamy Suresh, Kopelovich Levy, Inhibition of Azoxymethane-Induced Colorectal Cancer by CP-31398, a TP53 Modulator, Alone or in Combination with Low Doses of Celecoxib in Male F344 Rats, Cancer Research, 69, 20, 2009. Crossref

  52. Mohammed Altaf, Janakiram Naveena B., Madka Venkateshwar, Zhang Yuting, Singh Anil, Biddick Laura, Li Qian, Lightfoot Stanley, Steele Vernon E., Lubet Ronald A., Suen Chen S., Miller Mark Steven, Sei Shizuko, Rao Chinthalapally V., Intermittent Dosing Regimens of Aspirin and Naproxen Inhibit Azoxymethane-Induced Colon Adenoma Progression to Adenocarcinoma and Invasive Carcinoma, Cancer Prevention Research, 12, 11, 2019. Crossref

  53. Fuloria Shivkanya, Mehta Jyoti, Chandel Aditi, Sekar Mahendran, Rani Nur Najihah Izzati Mat, Begum M. Yasmin, Subramaniyan Vetriselvan, Chidambaram Kumarappan, Thangavelu Lakshmi, Nordin Rusli, Wu Yuan Seng, Sathasivam Kathiresan V., Lum Pei Teng, Meenakshi Dhanalekshmi Unnikrishnan, Kumarasamy Vinoth, Azad Abul Kalam, Fuloria Neeraj Kumar, A Comprehensive Review on the Therapeutic Potential of Curcuma longa Linn. in Relation to its Major Active Constituent Curcumin, Frontiers in Pharmacology, 13, 2022. Crossref

Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections Prices and Subscription Policies Begell House Contact Us Language English 中文 Русский Português German French Spain